Lundbeck announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Lu AH69593, the company's lead oral orexin 2 rece...
Private equity firm Warburg Pincus is reportedly close to acquiring Pantherx Rare, a leading US specialty pharmacy focused on rare and orphan diseases, in ...
Mabion S.A., a Polish biotechnology company, has signed a letter of intent (LoI) with French TechDev company Oddifact SAS to evaluate and advance...
Analytical Framework Combines AI-Powered Retinal Imaging with Proprietary Circular RNA Biomarkers to Unlock Scalable, Non-Invasive Pathway for Early-Stag...
With Proposal #6, AIDS group urges shareholders to vote to request the company produce a report on the impact of extended patent exclusivities on patie...
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...
Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infection HBeAg- cohort sample size increa...
Phase two collaboration aims to expand access to streamlined genomic workflows for infectious disease research Cepheid, a Danaher company and a leader i...
Sonogenetics, discovered by SonoNeu founder Sreekanth Chalasani, is a new modality using ultrasound to precisely control specific cells ‘tagged&r...
FDA Fast Track designation supports accelerated development and expedites regulatory review Norovirus is responsible for an estimated 685 million glob...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including...
— Fast Track Designation facilitates development and expedites regulatory review of therapies addressing serious conditions with significant unmet ...
© 2026 Biopharma Boardroom. All Rights Reserved.
